XoGlo is under clinical development by Kimera Labs and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XoGlo’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XoGlo overview
XoGlo is under development for the treatment of acute respiratory distress syndrome, post-covid inflammation, pneumonia caused by coronavirus disease 2019 (COVID-19) and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate comprises of exosomes derived from placental mesenchymal stem cells. It is administered through intravenous route.
Kimera Labs overview
Kimera Labs is involved in the production of perinatal mesenchymal stem cell exosome products used for cosmetic and research purposes. The company is headquartered in Miramar, Florida, the US.
For a complete picture of XoGlo’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
